Summary of safety and efficacy of COVID-19 vaccination in patients with multiple sclerosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F23%3AA2402L78" target="_blank" >RIV/61988987:17110/23:A2402L78 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/23:00130654
Result on the web
<a href="https://karger.com/ene/article/doi/10.1159/000529982/836848/Summary-of-Safety-and-Efficacy-of-COVID" target="_blank" >https://karger.com/ene/article/doi/10.1159/000529982/836848/Summary-of-Safety-and-Efficacy-of-COVID</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1159/000529982" target="_blank" >10.1159/000529982</a>
Alternative languages
Result language
angličtina
Original language name
Summary of safety and efficacy of COVID-19 vaccination in patients with multiple sclerosis
Original language description
Background: The SARS-CoV-2 pandemic represents one of the most challenging issues that have recently influenced everyday life in countries all over the world. Understanding the risk of this disease is of high importance in patients with multiple sclerosis (MS) as they represent a vulnerable population through their treatment with disease-modifying therapies (DMTs). Infective episodes may trigger relapses and lead to deterioration of the health condition. Summary: Vaccination is an important preventive measure against infectious diseases. In MS patients, concerns have been raised about the effectiveness of vaccines in patients on various immunomodulatory drugs and about their possible adverse effects including impairment of neurological functions. The objectives of this article were to summarize the current knowledge on immune responses to the COVID-19 vaccines and their safety in MS patients and to provide practical guidance based on the data available to date. Key Messages: Although MS is not associated with a higher risk of COVID-19, this infection can trigger relapses or pseudo-relapses. Vaccines against SARS-CoV-2 are recommended for all MS patients who are not in the active phase of the disease, despite the fact that there is still a lack of long-term reliable data on the effectiveness and safety of vaccines against COVID-19. Some DMTs can reduce vaccine humoral responses, but might still provide some protection and adequate T-cell response. To optimize the effectiveness of vaccination, the ideal timing of vaccine application and DMTs dosing regimen is crucial.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30302 - Epidemiology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Neurology
ISSN
0014-3022
e-ISSN
1421-9913
Volume of the periodical
—
Issue of the periodical within the volume
4
Country of publishing house
CH - SWITZERLAND
Number of pages
14
Pages from-to
263-276
UT code for WoS article
000947309800001
EID of the result in the Scopus database
2-s2.0-85169715310